Given this unfavorable prognostic value, STS patients with high level of PARP1 expression would warrant a more aggressive treatment plan, which might include PARP1 inhibitors possibly associated with trabectedin given the predictive value of high PARP1 expression (Grignani et al., 2018; Pignochino et al., 2017) or with other DNA‐damaging agents. This evidence concerns the gene PARP1 and telomere syndrome.